Parkin Somatic Mutations Link Melanoma and Parkinson's Disease

a.
Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
b.
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
c.
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel
d.
Oncology Institute, Edith Wolfson Medical Center, Holon 5822012, Israel
e.
Technion Smoler Proteomics Center, Faculty of Biology, Technion – Israel Institute of Technology, Haifa 32000, Israel
f.
Institut Gustave Roussy, INSERM U753, Villejuif 94805, France
g.
Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel

More Information

Corresponding author: E-mail address: carmitlevy@post.tau.ac.il (Carmit Levy)

摘要

- /
- /
- /
Abstract: Epidemiological studies suggest a direct link between melanoma and Parkinson's disease (PD); however, the underlying molecular basis is unknown. Since mutations in Parkin are the major driver of early-onset PD and Parkin was recently reported to play a role in cancer development, we hypothesized that Parkin links melanoma and PD. By analyzing whole exome/genome sequencing of Parkin from 246 melanoma patients, we identified five non-synonymous mutations, three synonymous mutations, and one splice region variant in Parkin in 3.6% of the samples. In vitro analysis showed that wild-type Parkin plays a tumor suppressive role in melanoma development resulting in cell-cycle arrest, reduction of metabolic activity, and apoptosis. Using a mass spectrometry-based analysis, we identified potential Parkin substrates in melanoma and generated a functional protein association network. The activity of mutated Parkin was assessed by protein structure modeling and examination of Parkin E3 ligase activity. The Parkin-E28K mutation impairs Parkin ubiquitination activity and abolishes its tumor suppressive effect. Taken together, our analysis of genomic sequence and in vitro data indicate that Parkin is a potential link between melanoma and Parkinson's disease. Our findings suggest new approaches for early diagnosis and treatment against both diseases.
- Melanoma /
- Parkinson's disease /
- Parkin /
- Mutation

HTML全文

参考文献(49)

[1]	Berger, M.F., Hodis, E., Heffernan, T.P. et al. Nature, 485 (2012),pp. 502-506
[2]	Bertoni, J.M., Arlette, J.P., Fernandez, H.H. et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study Arch. Neurol., 67 (2010),p. 347
[3]	Chen, D., Gao, F., Li, B. et al. Parkin mono-ubiquitinates Bcl-2 and regulates autophagy J. Biol. Chem., 285 (2010),pp. 38214-38223
[4]	Dutton-Regester, K., Gartner, J.J., Emmanuel, R. et al. A highly recurrent RPS27 5′UTR mutation in melanoma Oncotarget, 5 (2014),pp. 2912-2917
[5]	Fiala, K.H., Whetteckey, J., Manyam, B.V. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat. Disord., 9 (2003),pp. 321-327
[6]	Flaherty, K.T., Hodi, F.S., Fisher, D.E. From genes to drugs: targeted strategies for melanoma Nat. Rev. Cancer, 12 (2012),pp. 349-361
[7]	Fujiwara, M., Marusawa, H., Wang, H.Q. et al. Oncogene, 27 (2008),pp. 6002-6011
[8]	Gao, E., Liu, L., Zhu, M. et al. Inorg. Chem., 50 (2011),pp. 4732-4741
[9]	Gao, X., Simon, K.C., Han, J. et al. Family history of melanoma and Parkinson disease risk Neurology, 73 (2009),pp. 1286-1291
[10]	Guo, J.F., Xiao, B., Liao, B. et al. Mov. Disord., 23 (2008),pp. 2074-2079
[11]	Guo, J.F., Zhang, X.W., Nie, L.L. et al. J. Neurol., 257 (2010),pp. 1170-1175
[12]	Hampe, C., Ardila-Osorio, H., Fournier, M. et al. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity Hum. Mol. Genet., 15 (2006),pp. 2059-2075
[13]	Hanahan, D., Weinberg, R.A. Hallmarks of cancer: the next generation Cell, 144 (2011),pp. 646-674
[14]	Hedrich, K., Eskelson, C., Wilmot, B. et al. Mov. Disord., 19 (2004),pp. 1146-1157
[15]	Herrero Hernandez, E. Pigmentation genes link Parkinson's disease to melanoma, opening a window on both etiologies Med. Hypotheses, 72 (2009),pp. 280-284
[16]	Hershko, A., Ciechanover, A. The ubiquitin system Annu. Rev. Biochem., 67 (1998),pp. 425-479
[17]	Hodis, E., Watson, I.R., Kryukov, G.V. et al. A landscape of driver mutations in melanoma Cell, 150 (2012),pp. 251-263
[18]	Hu, H.H., Kannengiesser, C., Lesage, S. et al. J. Natl. Cancer Inst., 108 (2016)
[19]	Imai, Y., Soda, M., Takahashi, R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity J. Biol. Chem., 275 (2000),pp. 35661-35664
[20]	Inzelberg, R., Rabey, J., Melamed, E. et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease J. Neural. Transm., 118 (2011),pp. 1199-1207
[21]	Johnson, B.N., Berger, A.K., Cortese, G.P. et al. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax Proc. Natl. Acad. Sci. USA, 109 (2012),pp. 6283-6288
[22]	Kahle, P.J., Haass, C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep., 5 (2004),pp. 681-685
[23]	Kareus, S.A., Figueroa, K.P., Cannon-Albright, L.A. et al. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study Arch. Neurol., 69 (2012),pp. 1572-1577
[24]	Kay, D.M., Stevens, C.F., Hamza, T.H. et al. Neurology, 75 (2010),pp. 1189-1194
[25]	Krauthammer, M., Kong, Y., Ha, B.H. et al. Nat. Genet., 44 (2012),pp. 1006-1014
[26]	Letessier, A., Garrido-Urbani, S., Ginestier, C. et al. Oncogene, 26 (2007),pp. 298-307
[27]	Lim, K.L., Chew, K.C., Tan, J.M. et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation J. Neurosci., 25 (2005),pp. 2002-2009
[28]	Liu, R., Gao, X., Lu, Y. et al. Meta-analysis of the relationship between Parkinson disease and melanoma Neurology, 76 (2011),pp. 2002-2009
[29]	Lücking, C.B., Dürr, A., Bonifati, V. et al. N. Engl. J. Med., 342 (2000),pp. 1560-1567
[30]	Moore, D.J., West, A.B., Dikeman, D.A. et al. Parkin mediates the degradation-independent ubiquitination of Hsp70 J. Neurochem., 105 (2008),pp. 1806-1819
[31]	Narendra, D., Kane, L.A., Hauser, D.N. et al. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both Autophagy, 6 (2010),pp. 1090-1106
[32]	Nikolaev, S.I., Rimoldi, D., Iseli, C. et al. Nat. Genet., 44 (2012),pp. 133-139
[33]	Olsen, J.H., Friis, S., Frederiksen, K. Malignant melanoma and other types of cancer preceding Parkinson disease Epidemiology, 17 (2006),pp. 582-587
[34]	Oyama, G., Yoshimi, K., Natori, S. et al. Brain Res., 1352 (2010),pp. 214-222
[35]	Pan, T., Li, X., Jankovic, J. The association between Parkinson's disease and melanoma Int. J. Cancer, 128 (2011),pp. 2251-2260
[36]	Poulogiannis, G., McIntyre, R.E., Dimitriadi, M. et al. Proc. Natl. Acad. Sci. USA, 107 (2010),pp. 15145-15150
[37]	Ren, Y., Zhao, J., Feng, J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation J. Neurosci., 23 (2003),pp. 3316-3324
[38]	Romani-Aumedes, J., Canal, M., Martin-Flores, N. et al. Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease Cell Death Dis., 5 (2014),p. e1364
[39]	Sarraf, S.A., Raman, M., Guarani-Pereira, V. et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization Nature, 496 (2013),pp. 372-376
[40]	Shen, J., Cookson, M.R. Mitochondria and dopamine: new insights into recessive parkinsonism Neuron, 43 (2004),pp. 301-304
[41]	Shimura, H., Hattori, N., Kubo, S.-i. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat. Genet., 25 (2000),pp. 302-305
[42]	Sriram, S.R., Li, X., Ko, H.S. et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin Hum. Mol. Genet., 14 (2005),pp. 2571-2586
[43]	Sumrejkanchanakij, P., Eto, K., Ikeda, M.A. Cytoplasmic sequestration of cyclin D1 associated with cell cycle withdrawal of neuroblastoma cells Biochem. Biophys. Res. Commun., 340 (2006),pp. 302-308
[44]	Trempe, J.F., Sauve, V., Grenier, K. et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation Science, 340 (2013),pp. 1451-1455
[45]	Veeriah, S., Taylor, B.S., Meng, S. et al. Nat. Genet., 42 (2010),pp. 77-82
[46]	Wang, H., Liu, B., Zhang, C. et al. J. Pathol., 218 (2009),pp. 76-85
[47]	Xiong, D., Wang, Y., Kupert, E. et al. Am. J. Hum. Genet., 96 (2015),pp. 301-308
[48]	Xu, L., Lin, D.C., Yin, D. et al. An emerging role of PARK2 in cancer J. Mol. Med. (Berl), 92 (2014),pp. 31-42
[49]	Yeo, C.W., Ng, F.S., Chai, C. et al. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival Cancer Res., 72 (2012),pp. 2543-2553